1 5906 147 TAKAYASU ARTERITIS RISK LOCUS IN IL6 REPRESSES THE ANTI-INFLAMMATORY GENE GPNMB THROUGH CHROMATIN LOOPING AND RECRUITING MEF2-HDAC COMPLEX. OBJECTIVE: PREVIOUS WORK HAS REVEALED A GENETIC ASSOCIATION BETWEEN TAKAYASU ARTERITIS AND A NON-CODING GENETIC VARIANT IN AN ENHANCER REGION WITHIN IL6 (RS2069837 A/G). THE RISK ALLELE IN THIS VARIANT (ALLELE A) HAS A PROTECTIVE EFFECT AGAINST CHRONIC VIRAL INFECTION AND CANCER. THE GOAL OF THIS STUDY WAS TO CHARACTERISE THE FUNCTIONAL CONSEQUENCES OF THIS DISEASE-ASSOCIATED RISK LOCUS. METHODS: A COMBINATION OF EXPERIMENTAL AND BIOINFORMATICS TOOLS WERE USED TO MECHANISTICALLY UNDERSTAND THE EFFECTS OF THE DISEASE-ASSOCIATED GENETIC LOCUS IN IL6. THESE INCLUDED ELECTROPHORETIC MOBILITY SHIFT ASSAY, DNA AFFINITY PRECIPITATION ASSAYS FOLLOWED BY MASS SPECTROMETRY AND WESTERN BLOTTING, LUCIFERASE REPORTER ASSAYS AND CHROMOSOME CONFORMATION CAPTURE (3C) TO IDENTIFY CHROMATIN LOOPING IN THE IL6 LOCUS. BOTH CELL LINES AND PERIPHERAL BLOOD PRIMARY MONOCYTE-DERIVED MACROPHAGES WERE USED. RESULTS: WE IDENTIFIED THE MONOCYTE/MACROPHAGE ANTI-INFLAMMATORY GENE GPNMB,~520 KB FROM IL6, AS A TARGET GENE REGULATED BY RS2069837. WE REVEALED PREFERENTIAL RECRUITMENT OF MYOCYTE ENHANCER FACTOR 2-HISTONE DEACETYLASE (MEF2-HDAC) REPRESSIVE COMPLEX TO THE TAKAYASU ARTERITIS RISK ALLELE. FURTHER, WE DEMONSTRATED SUPPRESSION OF GPNMB EXPRESSION IN MONOCYTE-DERIVED MACROPHAGES FROM HEALTHY INDIVIDUALS WITH AA COMPARED WITH AG GENOTYPE, WHICH WAS REVERSED BY HISTONE DEACETYLASE INHIBITION. OUR DATA SHOW THAT THE RISK ALLELE IN RS2069837 REPRESSES THE EXPRESSION OF GPNMB BY RECRUITING MEF2-HDAC COMPLEX, ENABLED THROUGH A LONG-RANGE INTRACHROMATIN LOOPING. SUPPRESSION OF THIS ANTI-INFLAMMATORY GENE MIGHT MEDIATE INCREASED SUSCEPTIBILITY IN TAKAYASU ARTERITIS AND ENHANCE PROTECTIVE IMMUNE RESPONSES IN CHRONIC INFECTION AND CANCER. CONCLUSIONS: TAKAYASU ARTERITIS RISK LOCUS IN IL6 MIGHT INCREASE DISEASE SUSCEPTIBILITY BY SUPPRESSION OF THE ANTI-INFLAMMATORY GENE GPNMB THROUGH CHROMATIN LOOPING AND RECRUITMENT OF MEF2-HDAC EPIGENETIC REPRESSIVE COMPLEX. OUR DATA HIGHLIGHT LONG-RANGE CHROMATIN INTERACTIONS IN FUNCTIONAL GENOMIC AND EPIGENOMIC STUDIES IN AUTOIMMUNITY. 2019 2 5157 32 PRE-NEOPLASTIC EPIGENETIC DISRUPTION OF TRANSCRIPTIONAL ENHANCERS IN CHRONIC INFLAMMATION. CHRONIC PERIODONTITIS (CP) IS A CHRONIC INFLAMMATORY DISEASE INDEPENDENTLY ASSOCIATED WITH HIGHER INCIDENCE OF ORAL CAVITY SQUAMOUS CELL CARCINOMA (OSCC). HOWEVER, THE MOLECULAR MECHANISM RESPONSIBLE FOR THIS INCREASED INCIDENCE IS UNKNOWN. HERE WE PROFILED THE DNA METHYLOME OF CP PATIENTS AND HEALTHY CONTROLS AND COMPARED TO A LARGE SET OF OSCC SAMPLES FROM TCGA. WE OBSERVED A SIGNIFICANT OVERLAP BETWEEN THE ALTERED DNA METHYLATION PATTERNS IN CP AND IN OSCC, SUGGESTING AN EMERGENCE OF A PRE-NEOPLASTIC EPIGENOME IN CP. REMARKABLY, THE HYPERMETHYLATED CPGS IN CP WERE SIGNIFICANTLY ENRICHED FOR ENHANCER ELEMENTS. THIS ABERRANT ENHANCER METHYLATION IS FUNCTIONAL AND ABLE TO DISRUPT ENHANCER ACTIVITY BY PREVENTING THE BINDING OF CHROMATIN LOOPING FACTORS. THIS STUDY PROVIDES NEW INSIGHTS ON THE MOLECULAR MECHANISMS LINKING CHRONIC INFLAMMATION AND TUMOR PREDISPOSITION, HIGHLIGHTING THE ROLE OF EPIGENETIC DISRUPTION OF TRANSCRIPTIONAL ENHANCERS. 2016 3 5291 25 PROSTATE CARCINOGENESIS: INSIGHTS IN RELATION TO EPIGENETICS AND INFLAMMATION. PROSTATE CANCER IS A MULTIFACTORIAL DISEASE THAT MAINLY OCCURS DUE TO THE ACCUMULATION OF SOMATIC, GENETIC, AND EPIGENETIC CHANGES, RESULTING IN THE INACTIVATION OF TUMOR-SUPPRESSOR GENES AND ACTIVATION OF ONCOGENES. MUTATIONS IN GENES, SPECIFICALLY THOSE THAT CONTROL CELL GROWTH AND DIVISION OR THE REPAIR OF DAMAGED DNA, MAKE THE CELLS GROW AND DIVIDE UNCONTROLLABLY TO FORM A TUMOR. THE RISK OF DEVELOPING PROSTATE CANCER DEPENDS UPON THE GENE THAT HAS UNDERGONE THE MUTATION. IDENTIFYING SUCH GENETIC RISK FACTORS FOR PROSTATE CANCER POSES A CHALLENGE FOR THE RESEARCHERS. BESIDES GENETIC MUTATIONS, MANY EPIGENETIC ALTERATIONS, INCLUDING DNA METHYLATION, HISTONE MODIFICATIONS (METHYLATION, ACETYLATION, UBIQUITYLATION, SUMOYLATION, AND PHOSPHORYLATION) NUCLEOSOMAL REMODELING, AND CHROMOSOMAL LOOPING, HAVE SIGNIFICANTLY CONTRIBUTED TO THE ONSET OF PROSTATE CANCER AS WELL AS THE PROGNOSIS, DIAGNOSIS, AND TREATMENT OF PROSTATE CANCER. CHRONIC INFLAMMATION ALSO PLAYS A MAJOR ROLE IN THE ONSET AND PROGRESSION OF HUMAN CANCER, VIA MODIFICATIONS IN THE TUMOR MICROENVIRONMENT BY INITIATING EPITHELIALMESENCHYMAL TRANSITION AND REMODELING THE EXTRACELLULAR MATRIX. IN THIS ARTICLE, THE AUTHORS PRESENT A BRIEF HISTORY OF THE MECHANISMS AND POTENTIAL LINKS BETWEEN THE GENETIC ABERRATIONS, EPIGENETIC CHANGES, INFLAMMATION, AND INFLAMMASOMES THAT ARE KNOWN TO CONTRIBUTE TO THE PROGNOSIS OF PROSTATE CANCER. FURTHERMORE, THE AUTHORS EXAMINE AND DISCUSS THE CLINICAL POTENTIAL OF PROSTATE CARCINOGENESIS IN RELATION TO EPIGENETICS AND INFLAMMATION FOR ITS DIAGNOSIS AND TREATMENT.. 2021 4 3865 33 JAK2 REGULATES MISMATCH REPAIR PROTEIN-MEDIATED EPIGENETIC ALTERATIONS IN RESPONSE TO OXIDATIVE DAMAGE. AT SITES OF CHRONIC INFLAMMATION EPITHELIAL CELLS UNDERGO ABERRANT DNA METHYLATION THAT CONTRIBUTES TO TUMORIGENESIS. INFLAMMATION IS ASSOCIATED WITH AN INCREASE IN REACTIVE OXYGEN SPECIES (ROS) THAT CAUSE OXIDATIVE DNA DAMAGE, WHICH HAS ALSO BEEN LINKED TO EPIGENETIC ALTERATIONS. WE PREVIOUSLY DEMONSTRATED THAT IN RESPONSE TO ROS, MISMATCH REPAIR PROTEINS MSH2 AND MSH6 RECRUIT EPIGENETIC SILENCING PROTEINS DNA METHYLTRANSFERASE 1 (DNMT1) AND POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) MEMBERS TO SITES OF DNA DAMAGE, RESULTING IN TRANSCRIPTIONAL REPRESSION OF TUMOR SUPPRESSOR GENES (TSGS). HOWEVER, IT WAS UNCLEAR WHAT SIGNAL IS UNIQUE TO ROS THAT RESULTS IN THE CHROMATIN BINDING OF MSH2 AND MSH6. HEREIN, WE DEMONSTRATE THAT IN RESPONSE TO HYDROGEN PEROXIDE (H(2) O(2) ), JAK2 LOCALIZES TO THE NUCLEUS AND INTERACTS WITH MSH2 AND MSH6. INHIBITION OR KNOCKDOWN OF JAK2 REDUCES THE H(2) O(2) -INDUCED CHROMATIN INTERACTION OF MSH2, MSH6, DNMT1, AND PRC2 MEMBERS, REDUCES H(2) O(2) -INDUCED GLOBAL INCREASE IN TRIMETHYLATION OF LYSINE 27 OF HISTONE H3 (H3K27ME3), AND ABROGATES OXIDATIVE DAMAGE-INDUCED TRANSCRIPTIONAL REPRESSION OF CANDIDATE TSGS. MOREOVER, JAK2 MRNA EXPRESSION IS ASSOCIATED WITH CPG ISLAND METHYLATOR PHENOTYPE (CIMP) STATUS IN HUMAN COLORECTAL CANCER. OUR FINDINGS PROVIDE NOVEL INSIGHT INTO THE CONNECTION BETWEEN KINASE ACTIVATION AND EPIGENETIC ALTERATIONS DURING OXIDATIVE DAMAGE AND INFLAMMATION. ENVIRON. MOL. MUTAGEN. 60:308-319, 2019. (C) 2018 WILEY PERIODICALS, INC. 2019 5 5064 38 PHOSPHORYLATION OF RELA/P65 PROMOTES DNMT-1 RECRUITMENT TO CHROMATIN AND REPRESSES TRANSCRIPTION OF THE TUMOR METASTASIS SUPPRESSOR GENE BRMS1. THE MAJORITY OF PATIENTS WITH LUNG CANCER PRESENT WITH METASTATIC DISEASE. CHRONIC INFLAMMATION AND SUBSEQUENT ACTIVATION OF NUCLEAR FACTOR-KAPPAB (NF-KAPPAB) HAVE BEEN ASSOCIATED WITH THE DEVELOPMENT OF CANCERS. THE RELA/P65 SUBUNIT OF NF-KAPPAB IS TYPICALLY ASSOCIATED WITH TRANSCRIPTIONAL ACTIVATION. IN THIS REPORT WE SHOW THAT RELA/P65 CAN FUNCTION AS AN ACTIVE TRANSCRIPTIONAL REPRESSOR THROUGH ENHANCED METHYLATION OF THE BRMS1 (BREAST CANCER METASTASIS SUPPRESSOR 1) METASTASIS SUPPRESSOR GENE PROMOTER VIA DIRECT RECRUITMENT OF DNMT-1 (DNA (CYTOSINE-5)-METHYLTRANSFERASE 1) TO CHROMATIN IN RESPONSE TO TUMOR NECROSIS FACTOR (TNF). TNF-MEDIATED PHOSPHORYLATION OF S276 ON RELA/P65 IS REQUIRED FOR RELA/P65-DNMT-1 INTERACTIONS, CHROMATIN LOADING OF DNMT-1 AND SUBSEQUENT BRMS1 PROMOTER METHYLATION AND TRANSCRIPTIONAL REPRESSION. THE ABILITY OF RELA/P65 TO FUNCTION AS AN ACTIVE TRANSCRIPTIONAL REPRESSOR IS PROMOTER SPECIFIC, AS THE NF-KAPPAB-REGULATED GENE CIAP2 (CELLULAR INHIBITOR OF APOPTOSIS 2) IS TRANSCRIPTIONALLY ACTIVATED WHEREAS BRMS1 IS REPRESSED UNDER IDENTICAL CONDITIONS. SMALL-MOLECULE INHIBITION OF EITHER OF THE MINIMAL INTERACTING DOMAINS BETWEEN RELA/P65-DNMT-1 AND RELA/P65-BRMS1 PROMOTER ABROGATES BRMS1 METHYLATION AND ITS TRANSCRIPTIONAL REPRESSION. THE ABILITY OF RELA/P65 TO DIRECTLY RECRUIT DNMT-1 TO CHROMATIN, RESULTING IN PROMOTER-SPECIFIC METHYLATION AND TRANSCRIPTIONAL REPRESSION OF TUMOR METASTASIS SUPPRESSOR GENE BRMS1, HIGHLIGHTS A NEW MECHANISM THROUGH WHICH NF-KAPPAB CAN REGULATE METASTATIC DISEASE, AND OFFERS A POTENTIAL TARGET FOR NEWER-GENERATION EPIGENETIC ONCOPHARMACEUTICALS. 2012 6 6661 40 UPREGULATION OF DNA METHYLTRANSFERASE-MEDIATED GENE SILENCING, ANCHORAGE-INDEPENDENT GROWTH, AND MIGRATION OF COLON CANCER CELLS BY INTERLEUKIN-6. INFLAMMATORY BOWEL DISEASE IS CHARACTERIZED BY CHRONIC INFLAMMATION WHICH PREDISPOSES TO COLORECTAL CANCER. THE MECHANISMS BY WHICH INFLAMMATION PROMOTES TUMORIGENESIS ARE NOT FULLY KNOWN. WE AIMED TO INVESTIGATE THE LINKS BETWEEN COLONIC INFLAMMATION AND TUMORIGENESIS VIA EPIGENETIC GENE SILENCING. COLON CANCER SPECIMENS WERE ASSESSED FOR THE EXPRESSION OF DNA METHYLTRANSFERASE-1 (DNMT-1) USING IMMUNOHISTOCHEMISTRY. COLORECTAL CARCINOMA CELL LINES WERE ASSESSED FOR DNMT1 EXPRESSION, METHYLCYTOSINE CONTENT, PROMOTER METHYLATION, GENE EXPRESSION, AND TUMORIGENESIS IN RESPONSE TO INTERLEUKIN (IL)-6. DNMT1 WAS EXPRESSED AT HIGHER LEVELS IN BOTH THE PERITUMORAL STROMA AND TUMOR IN INFLAMMATORY BOWEL DISEASE-ASSOCIATED CANCERS COMPARED WITH SPORADIC COLON CANCERS. IL-6 TREATMENT OF COLON CANCER CELLS RESULTED IN AN INCREASE IN DNMT1 EXPRESSION, INDEPENDENT OF DE NOVO GENE EXPRESSION. IL-6 INCREASED THE METHYLATION OF PROMOTER REGIONS OF GENES ASSOCIATED WITH TUMOR SUPPRESSION, ADHESION, AND APOPTOSIS RESISTANCE. EXPRESSION OF A SUBSET OF THESE GENES WAS DOWNREGULATED BY IL-6, AN EFFECT THAT WAS PREVENTED BY PREINCUBATION WITH 5-AZADEOXYCYTIDINE, A DNMT1 INHIBITOR. ANCHORAGE-INDEPENDENT GROWTH AND MIGRATION OF COLON CANCER CELLS WAS ALSO INCREASED BY IL-6 IN A 5-AZADEOXYCYTIDINE-SENSITIVE MANNER. OUR RESULTS INDICATE THAT DNMT-MEDIATED GENE SILENCING MAY PLAY A ROLE IN INFLAMMATION-ASSOCIATED COLON TUMORIGENESIS. 2010 7 1978 25 EPIGENETIC ALTERATIONS IN CHOLANGIOCARCINOMA-SUSTAINED IL-6/STAT3 SIGNALING IN CHOLANGIO- CARCINOMA DUE TO SOCS3 EPIGENETIC SILENCING. CHOLANGIOCARCINOMA (CCA) IS A HIGHLY LETHAL MALIGNANT TUMOR ARISING FROM THE BILIARY TRACT EPITHELIUM, CHARACTERIZED BY ITS TYPICALLY LATE CLINICAL PRESENTATION AND LACK OF EFFECTIVE THERAPEUTIC MODALITIES. CHRONIC INFLAMMATORY CONDITIONS, INCLUDING PRIMARY SCLEROSING CHOLANGITIS, LIVER FLUKE INFESTATION AND HEPATOLITHIASIS, ARE LISTED IN THE RISK FACTORS, BUT FOR MOST CASES OF CCA THE CAUSE IS UNKNOWN. RECENT ADVANCES IN MOLECULAR PATHOGENESIS HAVE HIGHLIGHTED THE IMPORTANCE OF EPIGENETIC ALTERATIONS INCLUDING PROMOTER HYPERMETHYLATION AND HISTONE DEACETYLATION IN ADDITION TO GENETIC CHANGES IN THE PROCESS OF CHOLANGIOCARCINOGENESIS. THIS REVIEW PROVIDES A COMPREHENSIVE OVERVIEW OF THE GENES HYPERMETHYLATED IN CCA TO DATE AND THEIR PUTATIVE ROLES IN CHOLANGIOCARCINOGENESIS. AMONG GENES HYPERMETHYLATED, WE FOUND THE CPG ISLAND HYPERMETHYLATION IN SUPPRESSOR OF CYTOKINE SIGNALING 3 (SOCS3) GENE PROMOTER IN CCA. INTERLEUKIN-6 (IL-6)-MEDIATED SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION 3 (STAT3) ACTIVATION ARE ABERRANTLY SUSTAINED IN CCA CELLS, RESULTING IN RESISTANCE TO APOPTOSIS. SOCS3 CONTROLS THE IL-6/STAT3 SIGNALING PATHWAY BY A CLASSIC FEEDBACK LOOP. INDEED, SOCS3 EPIGENETIC SILENCING IS RESPONSIBLE FOR SUSTAINED IL-6/STAT3 SIGNALING IN CCA. THESE FINDINGS PROVIDE NEW PERSPECTIVES FOR EPIGENETIC THERAPY TO RESTORE SOCS3 IN THIS CANCER. 2009 8 3261 36 HEPATITIS C VIRUS-INDUCED UP-REGULATION OF PROTEIN PHOSPHATASE 2A INHIBITS HISTONE MODIFICATION AND DNA DAMAGE REPAIR. THE MOLECULAR MECHANISMS UNDERLYING HEPATOCARCINOGENESIS IN CHRONIC VIRAL HEPATITIS ARE POORLY UNDERSTOOD. A POTENTIAL TUMORIGENIC PATHWAY COULD INVOLVE PROTEIN PHOSPHATASE 2A (PP2A) AND PROTEIN ARGININE METHYLTRANSFERASE 1 (PRMT1), BECAUSE BOTH ENZYMES ARE DYSREGULATED IN CHRONIC HEPATITIS C, AND BOTH ENZYMES HAVE BEEN INVOLVED IN CHROMATIN REMODELING AND DNA DAMAGE REPAIR. WE USED CELL LINES THAT ALLOW THE INDUCIBLE EXPRESSION OF HEPATITIS C VIRUS PROTEINS (UHCV57.3) AND OF THE CATALYTIC SUBUNIT OF PP2A (UPP2A-C8) AS WELL AS HUH7.5 CELLS INFECTED WITH RECOMBINANT CELL CULTURE-DERIVED HEPATITIS C VIRUS (HCVCC) TO STUDY EPIGENETIC HISTONE MODIFICATIONS AND DNA DAMAGE REPAIR. THE INDUCTION OF VIRAL PROTEINS, THE OVEREXPRESSION OF PP2AC, OR THE INFECTION OF HUH7.5 CELLS WITH HCVCC RESULTED IN AN INHIBITION OF HISTONE H4 METHYLATION/ACETYLATION AND HISTONE H2AX PHOSPHORYLATION, IN A SIGNIFICANTLY CHANGED EXPRESSION OF GENES IMPORTANT FOR HEPATOCARCINOGENESIS, AND INHIBITED DNA DAMAGE REPAIR. OVEREXPRESSION OF PP2AC IN NIH-3T3 CELLS INCREASED ANCHORAGE-INDEPENDENT GROWTH. THESE CHANGES WERE PARTIALLY REVERSED BY THE TREATMENT OF CELLS WITH THE METHYL-GROUP DONOR S-ADENOSYL-L-METHIONINE (SAME). CONCLUSION: HEPATITIS C VIRUS-INDUCED OVEREXPRESSION OF PP2AC CONTRIBUTES TO HEPATOCARCINOGENESIS THROUGH DYSREGULATION OF EPIGENETIC HISTONE MODIFICATIONS. THE CORRECTION OF DEFECTIVE HISTONE MODIFICATIONS BY S-ADENOSYL-L-METHIONINE MAKES THIS DRUG A CANDIDATE FOR CHEMOPREVENTIVE THERAPIES IN PATIENTS WITH CHRONIC HEPATITIS C WHO ARE AT RISK FOR DEVELOPING HEPATOCELLULAR CARCINOMA. 2010 9 3796 30 INTERLEUKIN-6 PROMOTES TUMORIGENESIS BY ALTERING DNA METHYLATION IN ORAL CANCER CELLS. WORLDWIDE ORAL SQUAMOUS CELL CARCINOMA (OSCC) ACCOUNTS FOR MORE THAN 100,000 DEATHS EACH YEAR. CHRONIC INFLAMMATION CONSTITUTES ONE OF THE KEY RISK FACTORS FOR OSCC. ACCUMULATING EVIDENCE SUGGESTS THAT ABERRANT DNA METHYLATION MAY CONTRIBUTE TO OSCC TUMORIGENESIS. THIS STUDY INVESTIGATED WHETHER CHRONIC INFLAMMATION ALTERS DNA METHYLATION AND EXPRESSION OF CANCER-ASSOCIATED GENES IN OSCC. WE ESTABLISHED AN IN VITRO MODEL OF INTERLEUKIN (IL)-6 MEDIATING CHRONIC INFLAMMATION IN OSCC CELL LINES. THEREAFTER, WE MEASURED THE ABILITY OF IL-6 TO INDUCE GLOBAL HYPOMETHYLATION OF LONG INTERSPERSED NUCLEAR ELEMENT-1 (LINE-1) SEQUENCES, AS WELL AS CPG METHYLATION CHANGES USING MULTIPLE METHODOLOGIES INCLUDING QUANTITATIVE PYROSEQUENCING, METHYLATION-SPECIFIC MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION AND SENSITIVE MELTING ANALYSIS AFTER REAL-TIME-METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (PCR). GENE EXPRESSION WAS INVESTIGATED BY QUANTITATIVE REVERSE TRANSCRIPTASE-PCR. IL-6 INDUCED SIGNIFICANT GLOBAL LINE-1 HYPOMETHYLATION (P=0.016) IN OUR IN VITRO MODEL OF INFLAMMATORY STRESS IN OSCC CELL LINES. SIMULTANEOUSLY, IL-6 INDUCED CPG PROMOTER METHYLATION CHANGES IN SEVERAL IMPORTANT PUTATIVE TUMOR SUPPRESSOR GENES INCLUDING CHFR, GATA5 AND PAX6. METHYLATION CHANGES CORRELATED INVERSELY WITH THE CHANGES IN THE EXPRESSION OF CORRESPONDING GENES. OUR RESULTS INDICATE THAT IL-6-INDUCED INFLAMMATION PROMOTES TUMORIGENESIS IN THE ORAL CAVITY BY ALTERING GLOBAL LINE-1 HYPOMETHYLATION. IN ADDITION, CONCURRENT HYPERMETHYLATION OF MULTIPLE TUMOR SUPPRESSOR GENES BY IL-6 SUGGESTS THAT EPIGENETIC GENE SILENCING MAY BE AN IMPORTANT CONSEQUENCE OF CHRONIC INFLAMMATION IN THE ORAL CAVITY. THESE FINDINGS HAVE CLINICAL RELEVANCE, AS BOTH METHYLATION AND INFLAMMATION ARE SUITABLE TARGETS FOR DEVELOPING NOVEL PREVENTIVE AND THERAPEUTIC MEASURES. 2011 10 4951 27 PATHOGENESIS OF CHOLANGIOCARCINOMA: FROM GENETICS TO SIGNALLING PATHWAYS. CHOLANGIOCARCINOMA (CCA) IS A MALIGNANT TUMOUR OF BILE DUCT EPITHELIAL CELLS WITH DISMAL PROGNOSIS AND RISING INCIDENCE. CHRONIC INFLAMMATION RESULTING FROM LIVER FLUKE INFECTION, HEPATITIS AND OTHER INFLAMMATORY BOWEL DISEASES IS A MAJOR CONTRIBUTING FACTOR TO CHOLANGIOCARCINOGENESIS, LIKELY THROUGH ACCUMULATION OF SERIAL GENETIC AND EPIGENETIC ALTERATIONS RESULTING IN ABERRATION OF ONCOGENES AND TUMOUR SUPPRESSORS. RECENT STUDIES MAKING USE OF ADVANCES IN HIGH-THROUGHPUT GENOMICS HAVE REVEALED THE GENETIC LANDSCAPE OF CCA, GREATLY INCREASING OUR UNDERSTANDING OF ITS UNDERLYING BIOLOGY. A SERIES OF HIGHLY RECURRENT MUTATIONS IN GENES SUCH AS TP53, KRAS, SMAD4, BRAF, MLL3, ARID1A, PBRM1 AND BAP1, WHICH ARE KNOWN TO BE INVOLVED IN CELL CYCLE CONTROL, CELL SIGNALLING PATHWAYS AND CHROMATIN DYNAMICS, HAVE LED TO INVESTIGATIONS OF THEIR ROLES, THROUGH MOLECULAR TO MOUSE MODELLING STUDIES, IN CHOLANGIOCARCINOGENESIS. THIS REVIEW FOCUSES ON THE LANDSCAPE GENETIC ALTERATIONS IN CCA AND ITS FUNCTIONAL RELEVANCE TO THE FORMATION AND PROGRESSION OF CCA. 2015 11 3175 35 H2AX PHOSPHORYLATION REGULATED BY P38 IS INVOLVED IN BIM EXPRESSION AND APOPTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA CELLS INDUCED BY IMATINIB. INCREASING EVIDENCE SUGGESTS THAT HISTONE H2AX PLAYS A CRITICAL ROLE IN REGULATION OF TUMOR CELL APOPTOSIS AND ACTS AS A NOVEL HUMAN TUMOR SUPPRESSOR PROTEIN. HOWEVER, THE ACTION OF H2AX IN CHRONIC MYELOGENOUS LEUKEMIA (CML) CELLS IS UNKNOWN. THE DETAILED MECHANISM AND EPIGENETIC REGULATION BY H2AX REMAIN ELUSIVE IN CANCER CELLS. HERE, WE REPORT THAT H2AX WAS INVOLVED IN APOPTOSIS OF CML CELLS. OVEREXPRESSION OF H2AX INCREASED APOPTOTIC SENSITIVITY OF CML CELLS (K562) INDUCED BY IMATINIB. HOWEVER, OVEREXPRESSION OF SER139-MUTATED H2AX (BLOCKING PHOSPHORYLATION) DECREASED SENSITIVITY OF K562 CELLS TO APOPTOSIS. SIMILARLY, KNOCKDOWN OF H2AX MADE K562 CELLS RESISTANT TO APOPTOTIC INDUCTION. THESE RESULTS REVEALED THAT THE FUNCTION OF H2AX INVOLVED IN APOPTOSIS IS STRICTLY RELATED TO ITS PHOSPHORYLATION (SER139). OUR DATA FURTHER INDICATED THAT IMATINIB MAY STIMULATE MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) FAMILY MEMBER P38, AND H2AX PHOSPHORYLATION FOLLOWED A SIMILAR TIME COURSE, SUGGESTING A PARALLEL RESPONSE. H2AX PHOSPHORYLATION CAN BE BLOCKED BY P38 SIRNA OR ITS INHIBITOR. THESE DATA DEMONSTRATED THAT H2AX PHOSPHORYLATION WAS REGULATED BY P38 MAPK PATHWAY IN K562 CELLS. HOWEVER, THE P38 MAPK DOWNSTREAM, MITOGEN- AND STRESS-ACTIVATED PROTEIN KINASE-1 AND -2, WHICH PHOSPHORYLATED HISTONE H3, WERE NOT REQUIRED FOR H2AX PHOSPHORYLATION DURING APOPTOSIS. FINALLY, WE PROVIDED EPIGENETIC EVIDENCE THAT H2AX PHOSPHORYLATION REGULATED APOPTOSIS-RELATED GENE BIM EXPRESSION. BLOCKING OF H2AX PHOSPHORYLATION INHIBITED BIM GENE EXPRESSION. TAKEN TOGETHER, THESE DATA DEMONSTRATED THAT H2AX PHOSPHORYLATION REGULATED BY P38 IS INVOLVED IN BIM EXPRESSION AND APOPTOSIS IN CML CELLS INDUCED BY IMATINIB. 2014 12 1987 39 EPIGENETIC ALTERATIONS OF CXCL5 IN CR(VI)-INDUCED CARCINOGENESIS. CHRONIC EXPOSURE TO HEXAVALENT CHROMIUM COMPOUNDS [CR(VI)] IS ASSOCIATED WITH AN INCREASED RISK OF CANCERS, BUT THE MOLECULAR MECHANISMS REMAIN TO BE ELUCIDATED. IN THIS STUDY, WE FOUND THAT CXCL5 LEVELS IN PERIPHERAL BLOOD MONOCYTES (PBMCS) AND PLASMA FROM WORKERS WITH OCCUPATIONAL EXPOSURE TO CR(VI) WERE DRAMATICALLY UPREGULATED COMPARED TO NON-EXPOSURE HEALTHY SUBJECTS, AND PLASMA C-X-C MOTIF CHEMOKINE LIGAND 5 (CXCL5) CXCL5 LEVELS WERE POSITIVELY CORRELATED WITH CR CONCENTRATIONS IN SUBJECTS' TOENAILS. ZINC CHROMATE EXPOSED MICE SHOWED HIGHER LEVELS OF CXCL5 AND ITS RECEPTOR CXCR2 IN LUNG TISSUES, AND IN PBMCS. SIMILAR CXCL5 UPREGULATION WAS EVIDENT IN CR(VI)-INDUCED TRANSFORMED (CR-T) CELLS WITH LONG-TERM CR(VI) TREATMENT. MECHANISTIC STUDIES SHOWED THAT ELEVATED CXCL5 EXPRESSION LEVELS WERE REGULATED BY CR(VI)-INDUCED HISTONE MODIFICATIONS AND DNA HYPOMETHYLATION, AND THAT THE C-MYC/P300 COMPLEX WAS A KEY UPSTREAM REGULATOR OF HISTONE H3 ACETYLATION. CXCL5 OVEREXPRESSION PROMOTED CR(VI)-INDUCED THE EPITHELIAL TO MESENCHYME TRANSITION (EMT) BY UPREGULATING ZINC FINGER E-BOX BINDING HOMEOBOX 1 (ZEB1) TO PROMOTE TUMOR DEVELOPMENT. OUR FINDINGS IDENTIFY A NOVEL MECHANISM BY WHICH CXCL5 IS UPREGULATED AND PROMOTES EMT AND CARCINOGENESIS UPON CHRONIC CR(VI) EXPOSURE. OUR WORK ALSO IMPLIES THAT CXCL5 MRNA AND PROTEIN LEVELS WILL ELEVATE IN PBMCS AND SERUM AFTER OCCUPATIONAL CR(VI) EXPOSURE, WHICH MAY BE A POTENTIAL TARGET AND BIOMARKER FOR CANCER PREVENTION AND HEALTH SURVEILLANCE AMONG POPULATIONS EXPOSED TO CR(VI). 2022 13 5301 24 PROTEIN PHOSPHATASE 2A CATALYTIC SUBUNIT ALPHA PLAYS A MYD88-DEPENDENT, CENTRAL ROLE IN THE GENE-SPECIFIC REGULATION OF ENDOTOXIN TOLERANCE. MYD88, THE INTRACELLULAR ADAPTOR OF MOST TLRS, MEDIATES EITHER PROINFLAMMATORY OR IMMUNOSUPPRESSIVE SIGNALING THAT CONTRIBUTES TO CHRONIC INFLAMMATION-ASSOCIATED DISEASES. ALTHOUGH GENE-SPECIFIC CHROMATIN MODIFICATIONS REGULATE INFLAMMATION, THE ROLE OF MYD88 SIGNALING IN ESTABLISHING SUCH EPIGENETIC LANDSCAPES UNDER DIFFERENT INFLAMMATORY STATES REMAINS ELUSIVE. USING QUANTITATIVE PROTEOMICS TO ENUMERATE THE INFLAMMATION-PHENOTYPIC CONSTITUENTS OF THE MYD88 INTERACTOME, WE FOUND THAT IN ENDOTOXIN-TOLERANT MACROPHAGES, PROTEIN PHOSPHATASE 2A CATALYTIC SUBUNIT ALPHA (PP2AC) ENHANCES ITS ASSOCIATION WITH MYD88 AND IS CONSTITUTIVELY ACTIVATED. KNOCKDOWN OF PP2AC PREVENTS SUPPRESSION OF PROINFLAMMATORY GENES AND RESISTANCE TO APOPTOSIS. THROUGH SITE-SPECIFIC DEPHOSPHORYLATION, CONSTITUTIVELY ACTIVE PP2AC DISRUPTS THE SIGNAL-PROMOTING TLR4-MYD88 COMPLEX AND BROADLY SUPPRESSES THE ACTIVITIES OF MULTIPLE PROINFLAMMATORY/PROAPOPTOTIC PATHWAYS AS WELL, SHIFTING PROINFLAMMATORY MYD88 SIGNALING TO A PROSURVIVAL MODE. CONSTITUTIVELY ACTIVE PP2AC TRANSLOCATED WITH MYD88 INTO THE NUCLEI OF TOLERANT MACROPHAGES ESTABLISHES THE IMMUNOSUPPRESSIVE PATTERN OF CHROMATIN MODIFICATIONS AND REPRESSES CHROMATIN REMODELING TO SELECTIVELY SILENCE PROINFLAMMATORY GENES, COORDINATING THE MYD88-DEPENDENT INFLAMMATION CONTROL AT BOTH SIGNALING AND EPIGENETIC LEVELS UNDER ENDOTOXIN-TOLERANT CONDITIONS. 2013 14 1733 46 E-CADHERIN GENE RE-EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS BY HDAC INHIBITORS. BACKGROUND: THE TUMOR SUPPRESSOR GENE E-CADHERIN GENE IS FREQUENTLY SILENCED IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS AND RESULTS IN WNT-PATHWAY ACTIVATION. WE ANALYZED THE ROLE OF HISTONE EPIGENETIC MODIFICATIONS IN E-CADHERIN GENE SILENCING. METHODS: CLL SPECIMENS WERE TREATED WITH HISTONE DEACETYLASE INHIBITOR (HDACI) MS-275 AND ANALYZED FOR E-CADHERIN EXPRESSION WITH WESTERN BLOT AND RT-PCR ANALYSIS. THE DOWNSTREAM EFFECTS OF HDACI TREATED LEUKEMIC CELLS WERE STUDIED BY ANALYZING THE EFFECT ON WNT-PATHWAY SIGNALING. HDACI INDUCED ALTERATIONS IN E-CADHERIN SPLICING WERE INVESTIGATED BY TRANSCRIPT SPECIFIC REAL TIME PCR ANALYSIS. RESULTS: TREATMENT OF CLL SPECIMENS WITH HISTONE DEACETYLASE INHIBITORS (HDACI) TREATMENT RESULTED IN AN INCREASE OF THE E-CADHERIN RNA TRANSCRIPT (5 TO 119 FOLD INCREASE, N=10) IN EIGHT OUT OF TEN CLL SPECIMENS INDICATING THAT THIS GENE IS DOWN REGULATED BY HISTONE HYPOACETYLATION IN A MAJORITY OF CLL SPECIMENS. THE E-CADHERIN RE-EXPRESSION IN CLL SPECIMENS WAS NOTED BY WESTERN BLOT ANALYSIS AS WELL. BESIDES EPIGENETIC SILENCING ANOTHER MECHANISM OF E-CADHERIN INACTIVATION IS ABERRANT EXON 11 SPLICING RESULTING IN AN ALTERNATIVELY SPLICED TRANSCRIPT THAT LACKS EXON 11 AND IS DEGRADED BY THE NON-SENSE MEDIATED DECAY (NMD) PATHWAY. OUR CHROMATIN IMMUNOPRECIPITATION EXPERIMENTS SHOW THAT HDACI INCREASED THE ACETYLATION OF HISTONES H3 AND H4 IN THE E-CADHERIN PROMOTER REGION. THIS ALSO AFFECTED THE E-CADHERIN EXON 11 SPLICING PATTERN AS HDACI TREATED CLL SPECIMENS PREFERENTIALLY EXPRESSED THE CORRECTLY SPLICED TRANSCRIPT AND NOT THE EXON 11 SKIPPED ABERRANT TRANSCRIPT. THE RE-EXPRESSED E- CADHERIN BINDS TO BETA-CATENIN WITH INHIBITION OF THE ACTIVE WNT-BETA-CATENIN PATHWAY IN THESE CELLS. THIS RESULTED IN A DOWN REGULATION OF TWO WNT TARGET GENES, LEF AND CYCLIND1 AND THE WNT PATHWAY REPORTER. CONCLUSION: THE E-CADHERIN GENE IS EPIGENETICALLY MODIFIED AND HYPOACETYLATED IN CLL LEUKEMIC CELLS. TREATMENT OF CLL SPECIMENS WITH HDACI MS-275 ACTIVATES TRANSCRIPTION FROM THIS SILENT GENE WITH EXPRESSION OF MORE CORRECTLY SPLICED E-CADHERIN TRANSCRIPTS AS COMPARED TO THE ABERRANT EXON11 SKIPPED TRANSCRIPTS THAT IN TURN INHIBITS THE WNT SIGNALING PATHWAY. THE DATA HIGHLIGHTS THE ROLE OF EPIGENETIC MODIFICATIONS IN ALTERING GENE SPLICING PATTERNS. 2013 15 1454 32 DISCOVERY OF CANDIDATE DNA METHYLATION CANCER DRIVER GENES. EPIGENETIC ALTERATIONS, SUCH AS PROMOTER HYPERMETHYLATION, MAY DRIVE CANCER THROUGH TUMOR SUPPRESSOR GENE INACTIVATION. HOWEVER, WE HAVE LIMITED ABILITY TO DIFFERENTIATE DRIVER DNA METHYLATION (DNAME) CHANGES FROM PASSENGER EVENTS. WE DEVELOPED DNAME DRIVER INFERENCE-METHSIG-ACCOUNTING FOR THE VARYING STOCHASTIC HYPERMETHYLATION RATE ACROSS THE GENOME AND BETWEEN SAMPLES. WE APPLIED METHSIG TO BISULFITE SEQUENCING DATA OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), MULTIPLE MYELOMA, DUCTAL CARCINOMA IN SITU, GLIOBLASTOMA, AND TO METHYLATION ARRAY DATA ACROSS 18 TUMOR TYPES IN TCGA. METHSIG RESULTED IN WELL-CALIBRATED QUANTILE-QUANTILE PLOTS AND REPRODUCIBLE INFERENCE OF LIKELY DNAME DRIVERS WITH INCREASED SENSITIVITY/SPECIFICITY COMPARED WITH BENCHMARKED METHODS. CRISPR/CAS9 KNOCKOUT OF SELECTED CANDIDATE CLL DNAME DRIVERS PROVIDED A FITNESS ADVANTAGE WITH AND WITHOUT THERAPEUTIC INTERVENTION. NOTABLY, DNAME DRIVER RISK SCORE WAS CLOSELY ASSOCIATED WITH ADVERSE OUTCOME IN INDEPENDENT CLL COHORTS. COLLECTIVELY, METHSIG REPRESENTS A NOVEL INFERENCE FRAMEWORK FOR DNAME DRIVER DISCOVERY TO CHART THE ROLE OF ABERRANT DNAME IN CANCER. SIGNIFICANCE: METHSIG PROVIDES A NOVEL STATISTICAL FRAMEWORK FOR THE ANALYSIS OF DNA METHYLATION CHANGES IN CANCER, TO SPECIFICALLY IDENTIFY CANDIDATE DNA METHYLATION DRIVER GENES OF CANCER PROGRESSION AND RELAPSE, EMPOWERING THE DISCOVERY OF EPIGENETIC MECHANISMS THAT ENHANCE CANCER CELL FITNESS.THIS ARTICLE IS HIGHLIGHTED IN THE IN THIS ISSUE FEATURE, P. 2113. 2021 16 1122 38 COMPARISON OF GENE EXPRESSION PROFILES IN CHROMATE TRANSFORMED BEAS-2B CELLS. BACKGROUND: HEXAVALENT CHROMIUM [CR(VI)] IS A POTENT HUMAN CARCINOGEN. OCCUPATIONAL EXPOSURE HAS BEEN ASSOCIATED WITH INCREASED RISK OF RESPIRATORY CANCER. MULTIPLE MECHANISMS HAVE BEEN SHOWN TO CONTRIBUTE TO CR(VI) INDUCED CARCINOGENESIS, INCLUDING DNA DAMAGE, GENOMIC INSTABILITY, AND EPIGENETIC MODULATION, HOWEVER, THE MOLECULAR MECHANISM AND DOWNSTREAM GENES MEDIATING CHROMIUM'S CARCINOGENICITY REMAIN TO BE ELUCIDATED. METHODS/RESULTS: WE ESTABLISHED CHROMATE TRANSFORMED CELL LINES BY CHRONIC EXPOSURE OF NORMAL HUMAN BRONCHIAL EPITHELIAL BEAS-2B CELLS TO LOW DOSES OF CR(VI) FOLLOWED BY ANCHORAGE-INDEPENDENT GROWTH. THESE TRANSFORMED CELL LINES NOT ONLY EXHIBITED CONSISTENT MORPHOLOGICAL CHANGES BUT ALSO ACQUIRED ALTERED AND DISTINCT GENE EXPRESSION PATTERNS COMPARED WITH NORMAL BEAS-2B CELLS AND CONTROL CELL LINES (UNTREATED) THAT AROSE SPONTANEOUSLY IN SOFT AGAR. INTERESTINGLY, THE GENE EXPRESSION PROFILES OF SIX CR(VI) TRANSFORMED CELL LINES WERE REMARKABLY SIMILAR TO EACH OTHER YET DIFFERED SIGNIFICANTLY FROM THAT OF EITHER CONTROL CELL LINES OR NORMAL BEAS-2B CELLS. A TOTAL OF 409 DIFFERENTIALLY EXPRESSED GENES WERE IDENTIFIED IN CR(VI) TRANSFORMED CELLS COMPARED TO CONTROL CELLS. GENES RELATED TO CELL-TO-CELL JUNCTION WERE UPREGULATED IN ALL CR(VI) TRANSFORMED CELLS, WHILE GENES ASSOCIATED WITH THE INTERACTION BETWEEN CELLS AND THEIR EXTRACELLULAR MATRICES WERE DOWN-REGULATED. ADDITIONALLY, EXPRESSION OF GENES INVOLVED IN CELL PROLIFERATION AND APOPTOSIS WERE ALSO CHANGED. CONCLUSION: THIS STUDY IS THE FIRST TO REPORT GENE EXPRESSION PROFILING OF CR(VI) TRANSFORMED CELLS. THE GENE EXPRESSION CHANGES ACROSS INDIVIDUAL CHROMATE EXPOSED CLONES WERE REMARKABLY SIMILAR TO EACH OTHER BUT DIFFERED SIGNIFICANTLY FROM THE GENE EXPRESSION FOUND IN ANCHORAGE-INDEPENDENT CLONES THAT AROSE SPONTANEOUSLY. OUR ANALYSIS IDENTIFIED MANY NOVEL GENE EXPRESSION CHANGES THAT MAY CONTRIBUTE TO CHROMATE INDUCED CELL TRANSFORMATION, AND COLLECTIVELY THIS TYPE OF INFORMATION WILL PROVIDE A BETTER UNDERSTANDING OF THE MECHANISM UNDERLYING CHROMATE CARCINOGENICITY. 2011 17 4374 29 MISMATCH REPAIR PROTEINS RECRUIT DNA METHYLTRANSFERASE 1 TO SITES OF OXIDATIVE DNA DAMAGE. AT SITES OF CHRONIC INFLAMMATION, EPITHELIAL CELLS ARE EXPOSED TO HIGH LEVELS OF REACTIVE OXYGEN SPECIES AND UNDERGO CANCER-ASSOCIATED DNA METHYLATION CHANGES, SUGGESTING THAT INFLAMMATION MAY INITIATE EPIGENETIC ALTERATIONS. PREVIOUSLY, WE DEMONSTRATED THAT OXIDATIVE DAMAGE CAUSES EPIGENETIC SILENCING PROTEINS TO BECOME PART OF A LARGE COMPLEX THAT IS LOCALIZED TO GC-RICH REGIONS OF THE GENOME, INCLUDING PROMOTER CPG ISLANDS THAT ARE EPIGENETICALLY SILENCED IN CANCER. HOWEVER, WHETHER THESE PROTEINS WERE RECRUITED DIRECTLY TO DAMAGED DNA OR DURING THE DNA REPAIR PROCESS WAS UNKNOWN. HERE WE DEMONSTRATE THAT THE MISMATCH REPAIR PROTEIN HETERODIMER MSH2-MSH6 PARTICIPATES IN THE OXIDATIVE DAMAGE-INDUCED RECRUITMENT OF DNA METHYLTRANSFERASE 1 (DNMT1) TO CHROMATIN. HYDROGEN PEROXIDE TREATMENT INDUCES THE INTERACTION OF MSH2-MSH6 WITH DNMT1, SUGGESTING THAT THE RECRUITMENT IS THROUGH A PROTEIN-PROTEIN INTERACTION. IMPORTANTLY, THE REDUCTION IN TRANSCRIPTION FOR GENES WITH CPG ISLAND-CONTAINING PROMOTERS CAUSED BY OXIDATIVE DAMAGE IS ABROGATED BY KNOCKDOWN OF MSH6 AND/OR DNMT1. OUR FINDINGS PROVIDE EVIDENCE THAT THE ROLE OF DNMT1 AT SITES OF OXIDATIVE DAMAGE IS TO REDUCE TRANSCRIPTION, POTENTIALLY PREVENTING TRANSCRIPTION FROM INTERFERING WITH THE REPAIR PROCESS. THIS STUDY UNIQUELY BRINGS TOGETHER SEVERAL FACTORS THAT ARE KNOWN TO CONTRIBUTE TO COLON CANCER, NAMELY INFLAMMATION, MISMATCH REPAIR PROTEINS, AND EPIGENETIC CHANGES. 2016 18 2430 34 EPIGENETIC SILENCING OF MIR-210 INCREASES THE PROLIFERATION OF GASTRIC EPITHELIUM DURING CHRONIC HELICOBACTER PYLORI INFECTION. PERSISTENT COLONIZATION OF THE GASTRIC MUCOSA BY HELICOBACTER PYLORI (HP) ELICITS CHRONIC INFLAMMATION AND ABERRANT EPITHELIAL CELL PROLIFERATION, WHICH INCREASES THE RISK OF GASTRIC CANCER. HERE WE EXAMINE THE ABILITY OF MICRORNAS TO MODULATE GASTRIC CELL PROLIFERATION IN RESPONSE TO PERSISTENT HP INFECTION AND FIND THAT EPIGENETIC SILENCING OF MIR-210 PLAYS A KEY ROLE IN GASTRIC DISEASE PROGRESSION. IMPORTANTLY, DNA METHYLATION OF THE MIR-210 GENE IS INCREASED IN HP-POSITIVE HUMAN GASTRIC BIOPSIES AS COMPARED WITH HP-NEGATIVE CONTROLS. MOREOVER, SILENCING OF MIR-210 IN GASTRIC EPITHELIAL CELLS PROMOTES PROLIFERATION. WE IDENTIFY STMN1 AND DIMT1 AS MIR-210 TARGET GENES AND DEMONSTRATE THAT INHIBITION OF MIR-210 EXPRESSION AUGMENTS CELL PROLIFERATION BY ACTIVATING STMN1 AND DIMT1. TOGETHER, OUR RESULTS HIGHLIGHT INFLAMMATION-INDUCED EPIGENETIC SILENCING OF MIR-210 AS A MECHANISM OF INDUCTION OF CHRONIC GASTRIC DISEASES, INCLUDING CANCER, DURING HP INFECTION. 2014 19 880 22 CHRONIC CIGARETTE SMOKE-INDUCED EPIGENOMIC CHANGES PRECEDE SENSITIZATION OF BRONCHIAL EPITHELIAL CELLS TO SINGLE-STEP TRANSFORMATION BY KRAS MUTATIONS. WE DEFINE HOW CHRONIC CIGARETTE SMOKE-INDUCED TIME-DEPENDENT EPIGENETIC ALTERATIONS CAN SENSITIZE HUMAN BRONCHIAL EPITHELIAL CELLS FOR TRANSFORMATION BY A SINGLE ONCOGENE. THE SMOKE-INDUCED CHROMATIN CHANGES INCLUDE INITIAL REPRESSIVE POLYCOMB MARKING OF GENES, LATER MANIFESTING ABNORMAL DNA METHYLATION BY 10 MONTHS. AT THIS TIME, CELLS EXHIBIT EPITHELIAL-TO-MESENCHYMAL CHANGES, ANCHORAGE-INDEPENDENT GROWTH, AND UPREGULATED RAS/MAPK SIGNALING WITH SILENCING OF HYPERMETHYLATED GENES, WHICH NORMALLY INHIBIT THESE PATHWAYS AND ARE ASSOCIATED WITH SMOKING-RELATED NON-SMALL CELL LUNG CANCER. THESE CELLS, IN THE ABSENCE OF ANY DRIVER GENE MUTATIONS, NOW TRANSFORM BY INTRODUCING A SINGLE KRAS MUTATION AND FORM ADENOSQUAMOUS LUNG CARCINOMAS IN MICE. THUS, EPIGENETIC ABNORMALITIES MAY PRIME FOR CHANGING ONCOGENE SENESCENCE TO ADDICTION FOR A SINGLE KEY ONCOGENE INVOLVED IN LUNG CANCER INITIATION. 2017 20 5382 24 RECURRENT CHROMOSOMAL AND EPIGENETIC ALTERATIONS IN ORAL SQUAMOUS CELL CARCINOMA AND ITS PUTATIVE PREMALIGNANT CONDITION ORAL LICHEN PLANUS. HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) AFFECTS ABOUT 700.000 INDIVIDUALS PER YEAR WORLDWIDE WITH ORAL SQUAMOUS CELL CARCINOMA (OSCC) AS A MAJOR SUBCATEGORY. DESPITE A COMPREHENSIVE TREATMENT CONCEPT INCLUDING SURGERY, RADIATION, AND CHEMOTHERAPY THE 5-YEAR SURVIVAL RATE IS STILL ONLY ABOUT 50 PERCENT. CHRONIC INFLAMMATION IS ONE OF THE HALLMARKS OF CARCINOGENESIS. UNTIL NOW, LITTLE IS KNOWN ABOUT THE PREMALIGNANT STATUS OF ORAL LICHEN PLANUS (OLP) AND MOLECULAR ALTERATIONS IN OLP ARE STILL POORLY CHARACTERIZED. OUR STUDY AIMS TO DELINEATE DIFFERENTIAL DNA METHYLATION PATTERNS IN OLP, OSCC, AND NORMAL ORAL MUCOSA. BY APPLYING A BEAD CHIP APPROACH, WE IDENTIFIED ALTERED CHROMOSOMAL PATTERNS CHARACTERISTIC FOR OSCC WHILE FINDING NO RECURRENT ALTERATIONS IN OLP. IN CONTRAST, WE IDENTIFIED NUMEROUS ALTERATIONS IN THE DNA METHYLATION PATTERN IN OLP, AS COMPARED TO NORMAL CONTROLS, THAT WERE ALSO PRESENT IN OSCC. OUR DATA SUPPORT THE HYPOTHESIS THAT OLP IS A PRECURSOR LESION OF OSCC SHARING MULTIPLE EPIGENETIC ALTERATIONS WITH OSCC. 2019